A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses-Reference-Cited by-同舟云学术

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Published:2019-12-06 Issue:6470 Volume:366 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Steichen Jon M.¹²³^ORCID,Lin Ying-Cing⁴^ORCID,Havenar-Daughton Colin³⁵^ORCID,Pecetta Simone⁴^ORCID,Ozorowski Gabriel²³⁶,Willis Jordan R.¹²³^ORCID,Toy Laura³⁵^ORCID,Sok Devin¹²³^ORCID,Liguori Alessia¹²³^ORCID,Kratochvil Sven⁴^ORCID,Torres Jonathan L.²³⁶^ORCID,Kalyuzhniy Oleksandr¹²³^ORCID,Melzi Eleonora⁴^ORCID,Kulp Daniel W.¹²³⁷^ORCID,Raemisch Sebastian¹²³^ORCID,Hu Xiaozhen¹²³^ORCID,Bernard Steffen M.²³⁶,Georgeson Erik¹²³,Phelps Nicole¹²³^ORCID,Adachi Yumiko¹²³^ORCID,Kubitz Michael¹²³,Landais Elise¹²³^ORCID,Umotoy Jeffrey¹²³^ORCID,Robinson Amanda¹²³^ORCID,Briney Bryan¹²³⁸^ORCID,Wilson Ian A.²³⁶⁹^ORCID,Burton Dennis R.¹²³^ORCID,Ward Andrew B.²³⁶^ORCID,Crotty Shane³⁵¹⁰^ORCID,Batista Facundo D.⁴¹¹^ORCID,Schief William R.¹²³⁴^ORCID

Affiliation:

1. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

2. IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA 92037, USA.

3. Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037, USA.

4. The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.

5. Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

6. Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

7. Vaccine and Immune Therapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.

8. Center for Viral Systems Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

9. Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

10. Division of Infectious Diseases, Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

11. Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.

Abstract

Engineering better bnAbs A highly effective HIV vaccine has been the goal of vaccinologists for nearly 35 years. A successful vaccine would need to induce broadly neutralizing antibodies (bnAbs) that are capable of neutralizing multiple HIV strains (see the Perspective by Agazio and Torres). Steichen et al. report a strategy in which the first vaccine shot can lead to immune responses that generate desired bnAbs. By combining knowledge of human antibody repertoires and structure to guide design, they validated candidate immunogens through functional preclinical testing. Saunders et al. designed immunogens with differences in binding strength for bnAb precursors, which enabled selection of rare mutations after immunization. The immunogens promoted bnAb precursor maturation in humanized mice and macaques. Science , this issue p. eaax4380 , p. eaay7199 ; see also p. 1197

Funder

National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Ragon Institute of MGH, MIT and Harvard

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference61 articles.

1. An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic

2. Correlates of Protection Induced by Vaccination

3. Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses